论文部分内容阅读
推荐的消灭麻疹的免疫方案是对15月龄儿童接种麻疹疫苗,而南朝鲜在麻疹爆发时则选择在儿童6～9月龄时接种麻疹疫苗。由于近年来麻疹重又流行,并认为可能是由于疫苗病毒与当前野病毒的基因组差异导致疫苗效力下降所致,故作者进行了一项麻疹疫苗效力研究。 研究对象为1993年汉城和Seong-nam市麻疹爆发时的麻疹患儿和有家庭接触史的1～5岁儿童。共观察380例患儿(男:女=216:164),209例(55％)为5岁以下患儿,167例(43.9％)为<16月龄患儿,报告的年龄别发病率有两个高峰,最高峰在<16月龄组。第二个高峰在6～9岁组。在<16月龄组中免疫儿童仅占9.6％(16/167),16月龄～4岁组为59。
The recommended immunization program against measles is to vaccinate 15-month-old children against measles while South Korea chose to have measles vaccine at 6 to 9 months of age in the event of a measles outbreak. Since measles has re-emerged in recent years and the vaccine may have been attributed to a possible reduction in the vaccine’s potency due to the genomic differences between the vaccine virus and the current wild-type virus, the authors conducted a study on the efficacy of measles vaccine. The subjects studied were measles children at the time of the outbreak of measles in Seoul and Seong-nam in 1993 and children aged 1-5 years with a family history of exposure. A total of 380 children (male: female = 216: 164) were observed, 209 (55%) were children under 5 years of age and 167 (43.9%) were children <16 months of age with reported age- Two peaks, the highest peak in the <16-month-old group. The second peak in the 6 to 9 years old group. Only 16.6% (16/167) of children were immunized in the <16-month-old group and 59 in the 16-month-old group.